BRAF and melanoma: Similarly, Flt3L-poly I:C combined injection significantly induced the upregulating expression levels of CD86, CD40, and MHC II of tumor-infiltrating CD103+ DC and promoted DC immunogenic function, eventually enhancing antitumor responses synergized with anti-PD-L1 Ab treatment in BRAF-mutant and B16 melanoma mouse models (141).